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AbstrAct 
Background: Needle-exchange programs (NEPs) 
reduce infections in people who inject drugs. this 
study assesses the impact community pharma-
cies have had in the Needle-Exchange Program 
in Portugal since 2015.
Methods: Health gains were measured by the 
number of human immunodeficiency virus (HIV) 
and hepatitis c virus (HcV) infections averted, 
which were estimated, in each scenario, based 
on a standard model in the literature, calibrated 
to national data. the costs per infection were 
taken from national literature; costs of manu-
facturing, logistics and incineration of injection 
materials were also considered. the results were 
presented as net costs (i.e., incremental costs of 
the program with community pharmacies less the 
costs of additional infections avoided).
Results: considering a 5-year horizon, the 
Needle Exchange Program with community 
pharmacies would account for a 6.8% (n = 25) 
and a 6.5% reduction (n = 22) of HcV and HIV 
infections, respectively. the present value of 
net savings generated by the participation of 
community pharmacies in the program was 
estimated at €2,073,347. the average dis-
counted net benefit per syringe exchanged 
is €3.01, already taking into account a pay-
ment to community pharmacies per needle 
exchanged.
Interpretation: We estimate that the participa-
tion of community pharmacies in the Needle 
Exchange Program will lead to a reduction of HIV 
and HcV infections and will generate over €2 mil-
lion in savings for the health system.
Conclusions: the intervention is estimated to generate better health outcomes at lower costs, contribut-
ing to improving the efficiency of the public health system in Portugal. Can Pharm J (Ott) 2020;153:170-178.
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Introduction
The prevalence of human immunodeficiency 
virus (HIV), hepatitis C virus (HCV) and hepa-
titis B virus (HBV) is high among people who 
inject drugs (PWID),1 resulting in serious public 
health concerns. In PWID, infectious diseases 
are transmitted through 2 main channels: the 
sharing of drug injection equipment and unpro-
tected sexual activity. In Portugal, the last pub-
lished estimates of the number of PWID ranged 
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between 12,732 and 16,285, corresponding to a prevalence rate 
of 194.4 to 248.6 per 100,000 inhabitants aged 15 to 65.2 In 
2016, the prevalence of HIV and HCV for PWID in treatment 
for addiction in Portugal varied between 7%-27% and 67%-
88%, respectively, while 2.5% of screened PWID were HBV 
surface antigen positive.3
Needle-exchange programs (NEPs) improve access to kits 
with sterile drug-injecting equipment and condoms, reducing 
drug-related harms by decreasing transmission of infections 
among PWID.4-7
NEPs are available in 90 countries around the world,8 using 
different forms of distribution, ranging from mobile vans to 
home visits. Community pharmacies play an important role 
in these programs, mainly due to their accessibility in terms of 
opening hours and broad geographical distribution. In many 
countries, such as Australia,9 Belgium, France, Ireland, Nether-
lands, Slovenia, Spain and the United Kingdom,10 community 
pharmacies are an important distribution channel for the kits.
In Portugal, the NEP was launched in 1993 in commu-
nity pharmacies. After being launched, other entities joined 
the program, in particular, mobile vans (1994) and both gov-
ernmental and nongovernmental organizations (1999). Until 
2005, community pharmacies had a dominant role in the nee-
dle distribution network.11-17
Following a request by the National Committee Against 
AIDS (a governmental committee), a private consulting com-
pany performed an economic evaluation of the program in 
2002.18 The results showed that the NEP in community phar-
macies in Portugal was cost-effective, as it generated better 
health outcomes while lowering costs, with cost savings due 
to averted HIV and HCV infections adding up to €405 million 
(between 1993 and 2001).
From 1993 to 2012, community pharmacies participating 
in the NEP did not receive any public funding and provided 
these services pro bono. Due to the economic crisis, the com-
munity pharmacies (which are privately owned) suspended 
their participation in the program in 2013, rejoining it 2 years 
later after signing an agreement with the government that 
enhanced the expansion of the role of community pharma-
cies, particularly in relation to the provision of health services. 
Currently, the following entities are actively participating in 
the program: primary health care centres, governmental 
and nongovernmental organizations, mobile vans and com-
munity pharmacies. The program allows PWID to drop off 
used injecting drug equipment and collect a kit containing 2 
sterile needles and syringes, 2 alcohol swabs, 2 ampoules of 
double-distilled water, 2 citric acid sachets, 2 filters, 2 contain-
ers for drug preparation (clean cups) and 1 condom. This kit is 
financed by the government.
Since the first economic study in 2002,18 significant changes 
have occurred in areas such as the frequencies of the types of 
drugs consumed, consumption habits and accessibility to the 
NEP, as well as in the epidemiology of HIV and HCV among 
PWID in Portugal. Therefore, the objective of this study was 
to conduct a prospective cost-effectiveness analysis compar-
ing the current (since 2015) scenario of the NEP with par-
ticipation of community pharmacies (intervention scenario) 
versus a scenario without participation of community phar-
macies (status quo scenario). The results of this analysis are 
relevant to all stakeholders and to inform health care policy 
decision-making.
KNoWlEdgE INto PrActIcE 
 • Needle-exchange programs are available in 90 
countries around the world, and use different forms 
of distribution, ranging from mobile vans to home 
visits, with community pharmacies usually playing an 
important role in the program due to their accessibility 
in terms of opening hours and broad geographical 
distribution.
 • this study shows that, in Portugal, the participation of 
community pharmacies in a needle-exchange program 
has the potential to reduce HIV and HcV infections 
while saving above €2M for the health system.
 • community pharmacies may increase their impact 
on society by joining the needle-exchange programs, 
which may be a cost-effective strategy even in a setting 
where consumption of injectable drugs is decreasing.
MIsE EN PrAtIQUE dEs 
coNNAIssANcEs                                 
 • les programmes d’échange de seringues sont 
disponibles dans 90 pays du monde entier et 
utilisent différentes formes de distribution, allant 
des camionnettes mobiles aux visites à domicile. les 
pharmacies communautaires jouent généralement un 
rôle important dans le programme en raison de leur 
accessibilité en termes d’heures d’ouverture et de leur 
vaste répartition géographique.
 • cette étude montre qu’au Portugal, la participation 
des pharmacies communautaires à un programme 
d’échange de seringues a le potentiel de réduire les 
infections par le VIH et le VHc tout en permettant au 
système de santé d’économiser plus de 2 millions 
d’euros.
 • les pharmacies communautaires peuvent accroître leur 
impact sur la société en participant aux programmes 
d’échange de seringues, ce qui peut constituer une 
stratégie rentable même dans un contexte où la 
consommation de drogues injectables diminue.
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Methods
The clinical benefits of the NEP were estimated as the number 
of HIV and HCV infections averted due to the participation 
of community pharmacies in the program. Therefore, health 
gains associated with the intervention scenario were computed 
as the difference between the HIV and HCV new infections in 
the scenarios with and without the participation of community 
pharmacies.
The incremental costs of including community pharma-
cies in the Portuguese NEP were computed as the difference 
between the additional costs of the NEP with community 
pharmacies and the savings associated with the number of 
additionally averted HIV and HCV infections.
A time horizon of 5 years was considered in the analysis of 
the number of infections. Lifetime costs associated with treat-
ments of these infections were discounted at a 5% rate, as rec-
ommended by the National Authority of Medicines and Health 
Products (INFARMED) guidelines.19 The results are presented 
in terms of the value of the difference in costs between the sce-
nario of the NEP with community pharmacies and the scenario 
without community pharmacies. There were 2 possible results: 1) 
the difference in costs is positive, meaning that the intervention 
increases costs, and 2) the difference is negative, meaning that 
there are (positive) “net savings” associated with the intervention.
In the base-case scenario, the participation of community 
pharmacists in the NEP was assumed to be complementary to 
the other exchange locations available in the status quo sce-
nario. In a sensitivity analysis, a scenario where community 
pharmacies partially substitute for other NEP distribution sites 
was considered.
As this study is based on secondary and aggregate data, it 
was not necessary to get Institutional Ethics Review Board 
approval.
Health benefits
The number of new infections occurring in each scenario 
was separately estimated for HIV and HCV using the model 
presented by Jacobs et al.,20 based on the original equation by 
Kaplan and O’Keefe.21
The model’s structural equation is
No. of new infections = −( ) −( ) − −( )1 1 1 1q N s q t m* * * *[ * ],θ
where q is the disease prevalence in the PWID population, q is 
the probability of effectively cleaning the drug-injecting equip-
ment, N is the number of circulating needles, s is the needle-
sharing rate, t is the probability of infection per single injection 
with an infected needle and m is the number of individuals 
sharing the same needle.
The infection incidence depends on the susceptible popu-
lation of PWID [ ]1−( )q , the number of unclean and shared 
needles in circulation [ * * ]1−( )θ N s , and the probability of 
infection per sharing event [ * ]1 1− −( )q t m , which increases 
nonlinearly with the number of individuals sharing the same 
needle (m).
The model assumes that the number of needles in circula-
tion (N) in a given moment is stable, as in Kaplan and O’Keefe’s 
circulation theory.21 According to this theory, the infection inci-
dence decreases because the intervention reduces needles’ aver-
age circulation time and therefore the exposure time, decreasing 
the probability of infection per sharing episode. In other words, 
the intervention has an impact only on the sharing rate of the 
needle(s) and not on the number of needles in circulation (N).
The calibration of the equations is identical for both HIV 
and HCV infections, except for the parameters of disease prev-
alence (q) and the probability of infection per shared injec-
tion (t). The equation is calibrated according to 2 principles: 
1) in the status quo scenario, estimates of the number of new 
cases should be consistent with the historical incidence rates 
among PWID and their trends, and 2) calibration should use 
the best-available information for the equation’s epidemiologi-
cal parameters.
Regarding HIV incidence, national public authorities pub-
lish annually the number of notifications of HIV infections by 
transmission mode, including injecting drug use.22 The HIV 
incidence rate between 2015 and 2019 was extrapolated using 
a regression model where the number of new cases of HIV 
among PWID between 2004 and 2014 is explained by time. 
Figure 1 shows the model and its good fit (R2 = 92%). The 
registry of HIV notifications is considered the best source of 
information on incidence because HIV has been listed among 
compulsory notifiable diseases since 2005.
From 2014 onwards, the number of infections was pre-
dicted to decrease. Between 2015 and 2019, the number of new 
cases in the status quo scenario was estimated at 81, 63, 63, 50 
and 39, respectively.
The number of HIV notifications among PWID in Portugal 
since 2004, as well as the number predicted for the years after, 
is shown in Figure 1. Information regarding HCV incidence 
was scarcer and less systematically collected. The most recently 
published data by the Directorate General of Health report 45 
cases of acute infections in 2008 in the general population. 
Other published results regarding overall HCV incidence rates 
in Portugal are heterogeneous, ranging between 0.37/100,000 
and 8/100,000 inhabitants,22-25 corresponding to a range from 
a low of 37 up to a high of 810 new cases per year.
Following a personal communication with Professor Homie 
Razavi (from the Center for Disease Analysis [CDA]), the 
number of new cases of HCV among PWID in Portugal was 
estimated at 94 in 2014. This estimate was considered conser-
vative given the information available and was used to calibrate 
the first year of the status quo scenario.
The parameters considered constant for HCV along the time 
horizon are the probability of infection per single injection (t), the 
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number of individuals sharing the same needle (m) and the prob-
ability of effectively cleaning the drug-injecting equipment (q).
The model was calibrated with prevalence rates of HIV 
declining over time and constant rates of HCV. In line with 
the annual report by the General Directorate for Intervention 
on Addictive Behaviours and Dependencies (SICAD), pub-
lished in 2014,26 and Marinho et al.,27 prevalence estimations 
of HIV and HCV were 24% and 92% among PWID, respec-
tively. Additionally, the number of circulating needles in 2014 
was estimated at 1,200,277, which is the moving average of the 
TaBle 1 Parameters used to calibrate the model equations
Variable Value Source Constant
Probability of HIV infection per single injection (t
HIV
) 0.7% based on Public Health Agency of 
canada (2012)28
Yes
Probability of HcV infection per single injection (t
HcV
) 1.5% based on UK Ministry of Health (2009)29 Yes
Number of individuals sharing the same needle (m) 1.38 Jacobs et al. (1999)20 Yes
Probability of effectively cleaning the drug-injecting 
equipment (q)
7.7% based on Mendes et al. (2003)30 Yes
HIV prevalence among PWId (q
HIV
) 14.5%-23.7% sIcAd (2014)26 and authors’ estimates No
HcV prevalence among PWId (q
HcV
) 92.2% Marinho et al. (2001)27 and authors’ 
estimates
Yes
Number of circulating needles (N) 770,555-
1,200,277
dgs (2015)17 and authors’ estimates No
sharing rate (s) in status quo scenario 1%-9.8% Mendes et al. (2003)30 and sIcAd 
(2012)31
No
change in sharing rate (s) in intervention scenario –7.7% to 3.7% Assumption and authors’ estimates No
dgs, directorate-general of Health; HcV, hepatitis c virus; HIV, human immunodeficiency virus; PWId, people who inject drugs; sIcAd, general 
directorate for Intervention on Addictive behaviours and dependencies.
FIguRe 1 data and regression estimates of human immunodeficiency virus incidence in people who 
inject drugs
source: INsA (2014) and authors’ estimates.20
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number of needles exchanged in 2013, 2014 and 2015 (an esti-
mate was used for 2015).17
The parameters used to calibrate the model are summa-
rized in Table 1. The sharing rate decrease associated with the 
intervention was assumed to be half of the percentage increase 
of exchanged needles in 2015 and 2016. In other words, if the 
number of needles exchanged increases, the circulation time 
drops, as does the probability of sharing a specific needle. 
The analysis assumes that if the number of needles exchanged 
increases by 10%, the sharing rate will be proportionately 5% 
lower. The number of needles exchanged by community phar-
macies in 2015 was estimated at 87,761, based on the estimates 
available up to November 2015, an increase of roughly 7%. The 
number was estimated to reach 169,347 from 2016 onwards. 
The estimate of the future number of needles exchanged took 
into consideration the increasing trend in the number of com-
munity pharmacies participating in the program. According to 
data provided to the authors by the Portuguese National Phar-
macy Association, in November 2015, there were 426 commu-
nity pharmacies actively participating across the country and 
the average number of needles exchanged per month by each 
community pharmacy in November 2015 was 94. The result-
ing proportional reduction of the sharing rate in the interven-
tion scenario was then estimated at 3.7% and 7.7% in 2015 and 
2016, respectively, and assumed constant from 2016 onwards.
Cost difference
Costs incurred by community pharmacies and other entities 
participating in the production—distribution, collection and 
incineration of the kits distributed in community pharmacies—
were considered incremental costs associated with the inter-
vention scenario. A panel of pharmacies that had previously 
participated in the NEP was convened and consulted to iden-
tify and estimate the costs incurred by community pharmacies, 
including costs related to storage, logistics and labour costs of 
providing the service. Costs incurred by other entities, out-
side the community pharmacies, were retrieved from public 
contracts available online32 and included production, storage, 
distribution and incineration of the drug-injecting equipment. 
Cost estimates included a predicted (but nonexistent at the 
time, in 2015) remuneration for community pharmacies per 
needle exchanged of €2.5.
TaBle 2 Estimates of HIV and HcV treatment costs in Portugal
Infection Therapy Discounted value (€) Source
HIV raltegravir 215,194 chaudhary et al. (2010)33
Efavirenz 213,251
lopinavir 220,349




HcV, genotype 1 
naive
sofosbuvir/peginterferon + ribavirin 65,519 Félix et al. (2014)
35
telaprevir/peginterferon + ribavirin 58,059
boceprevir/peginterferon + ribavirin 58,222
Peginterferon + ribavirin 47,422
HcV, genotype 3 sofosbuvir/peginterferon + ribavirin 63,383
telaprevir/peginterferon + ribavirin EXP 63,736
boceprevir/peginterferon + ribavirin EXP 43,454
Peginterferon + ribavirin 42,582
HcV genotype 
4/5/6
sofosbuvir/peginterferon + ribavirin 59,128
Peginterferon + ribavirin 46,633
EXP, people with prior exposure; HcV, hepatitis c virus; HIV: human immunodeficiency virus.
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Direct lifetime health care costs associated with the infec-
tions were retrieved from publications by other authors. The 
values retrieved are presented in Table 2. Given the estimates 
available,33-35 the authors considered the most conservative cost 
estimate for HIV (€213,251). Regarding HCV, the cost used was 
the most conservative cost estimate for genotype 1 (€47,422), 
since this is the most prevalent genotype in Portugal.23,36-39
The HIV and HCV cost estimates in the literature assume 
that the evaluation time frame starts when the treatment starts. 
Thus, the lifetime cost estimates were additionally discounted 
in order to consider a lag of 3 and 15 years between the tim-
ing of the infection and the initiation of treatment of HIV and 
HCV, respectively.
Univariate sensitivity analyses were performed to assess 
the robustness of the base case. In the sensitivity analyses, the 
base-case calibration was varied in terms of discount rate (3% 
instead of 5%), lifetime infections’ costs (–30%) and sharing 
rate decrease associated with intervention (–30% compared 
to base-case scenario). A scenario excluding the impact of the 
intervention on HCV incidence was analyzed. Since the substi-
tutability between distribution channels is unknown, the pos-
sibility of some substitution between distribution sites was also 
explored. In particular, we considered a scenario where for each 
3 needles exchanged in the community pharmacies, there is 1 
less needle exchanged in the other distribution channels (1/3 
substitution). This scenario translates to a reduction in the ben-
efits associated with the intervention, since it is assumed that 
1/3 of the needle exchanges in community pharmacies would 
have occurred anyway, with no reduction in the overall costs 
of running the program in the community pharmacies. Also, it 
was conservatively assumed that there would be no reductions 
in the costs associated with running the NEP in other networks.
Results
The model estimated that, in a 5-year time horizon, the partici-
pation of community pharmacies in the NEP would reduce by 
25 the number of new HCV cases and by 22 the number of new 
HIV cases. In other words, over 5 years, community pharmacies 
might contribute to a reduction of 6.8% and 6.5% in HCV and 
HIV infections, respectively, among PWID in Portugal.
The overall costs per needle exchanged, including costs 
incurred outside the community pharmacies and their fees 
(which includes costs inside the community pharmacies), were 
estimated at €3.09. The number of needles exchanged was fore-
casted at 87,761 in the first intervention year and 169,347 in 
the following years. The incremental annual cost of the inter-
vention was estimated at €271,269 in 2015 and at €523,452 
from 2016 onwards.
The present value of lifetime costs associated with infec-
tions was estimated at €184,214 and €22,811 for HIV and HCV, 
respectively. The results in terms of net costs (i.e., the cost of the 
infections avoided less the incremental costs of the NEP with 
community pharmacy participation) are summarized in Table 3.
For each period, the savings associated with the additional 
infections avoided were higher than the incremental costs of 
the intervention (i.e., the intervention scenario is a dominant 
strategy when compared to the status quo scenario).
The discounted savings over a 5-year horizon were esti-
mated to be €2,073,347. Equivalently, each needle exchanged 
by the NEP in community pharmacies results, on average, in 
€3.01 of savings for taxpayers.
Sensitivity analysis proved the intervention scenario to be 
a robust dominant strategy. A 30% decrease in the infections’ 
costs had the highest impact on results, with a 61% reduction 
in net savings; an alternative 3% discount rate, lower than the 
national Portuguese guidelines’ base case but recommended 
by the Centers for Disease Control and Prevention for the 
cost-effectiveness analysis of community public health pre-
vention interventions,40 increased the savings by 22%; reduc-
ing the impact of the intervention on the needle-sharing rate 
(parameter s) by 20% reduced net savings by 41%. In the sce-
nario where HCV prevention benefits are ignored, the NEP 
with community pharmacies persists as a dominant interven-
tion with discounted net savings above €1.5 million, a 25% 
reduction versus the base case. Finally, in the scenario where 
the NEP in community pharmacies is considered to substitute 






of the NeP in 
pharmacies
Infections avoided
Saving associated with 
infections avoided (€)
Net savings (€)HCV HIV HCV HIV
2015 87,761 271,269 5 4 105,359 700,400 534,489
2016 169,347 523,452 6 6 147,976 1,150,455 774,979
2017 169,347 523,452 5 5 124,300 894,796 495,644
2018 169,347 523,452 5 4 105,937 710,154 292,639
2019 169,347 523,452 4 3 89,170 553,918 119,636
HcV, hepatitis c virus; HIV, human immunodeficiency virus; NEP, needle exchange program.
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for other distribution networks by 1/3, the intervention is no 
longer dominant but the present value of the cost per averted 
infection was estimated at €4085.
Discussion
The results of this analysis comparing a scenario with the 
participation of community pharmacies in the NEP versus a 
status quo scenario showed that community pharmacy-based 
needle exchange is a dominant strategy, generating higher 
health benefits and simultaneously costs savings for society. 
This result proved to be robust through a variety of sensitivity 
analyses where the parameters in the model associated with 
the highest uncertainty were varied. In all sensitivity analyses, 
the participation of community pharmacies in the NEP was a 
cost-effective strategy (with a cost per averted infection lower 
than €4100 in the worst case studied and positive net savings 
[dominant strategy] in all other cases).
We used a model from the literature20,41,42 to estimate the 
number of HIV and HCV infections that were averted. We 
were conservative in the values used for calibrating the model. 
For example, HIV prevalence estimates used in the model were 
those leading to HIV incidence rates in line with the number of 
new cases notified in Portugal. This approach underestimates 
the potential health gains, due to the well-known notification 
bias. The use of a higher disease prevalence when calibrating 
the model would have led to higher health benefits. Further-
more, we also consider the model itself to be conservative, since 
it includes all costs of drug-injecting equipment but not all the 
benefits related to the NEP. For example, the model does not 
take into account the potential beneficial impact of the NEP on 
the transmission of other illnesses, such as HBV and tubercu-
losis. Moreover, the kits dispensed under the NEP also include 
condoms, which aim to reduce sexually transmitted diseases 
and unwanted pregnancies. Consideration of these potential 
health benefits would improve the cost-effectiveness of the 
intervention program.
The comparability of the results across countries is diffi-
cult to determine due to differences in costs, PWID behaviour 
and infections’ prevalence and time horizon considered in the 
analysis, among other aspects. Furthermore, most of the litera-
ture presents cost-effectiveness analyses of NEP (considered as 
a whole) versus no NEP,20,43-46 while the current study repre-
sents a cost-effectiveness analysis comparing the effectiveness 
of the Portuguese distribution network without community 
pharmacies with a network including community pharmacies. 
Nevertheless, the overall findings of the present study are in 
line with those reported in the literature, which also conclude 
that the NEP is a cost-effective strategy (regardless of the dis-
tribution site) in other countries.18,41-44
Conclusion
The estimates presented in this work show that the participa-
tion of community pharmacies in the needle-exchange pro-
gram in Portugal has the potential to reduce HIV and HCV 
infections while saving over €2 million for the health system. 
Therefore, the participation of community pharmacies in 
this program is a dominant strategy compared to a program 
without them. The intervention generates better health out-
comes at lower costs than those of the NEP without the com-
munity pharmacies, contributing to improving the efficiency 
of the public health system in Portugal. Although not easily 
geographically generalizable outside Portugal, our findings 
suggest that the inclusion of community pharmacies in the 
distribution network of kits in the context of a NEP is a cost-
effective strategy even in a setting where the consumption of 
injectable drugs is decreasing. ■
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